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Purpose: We report results of a pivotal prospective clinical trial that compared standard surgical repair with endovascular
exclusion of abdominal aortic aneurysm (AAA) with the Talent LPS stent graft system.
Methods: Between March 24, 1999, and September 19, 2000, 240 patients with AAA who underwent stent graft
placement and 126 patients who concurrently underwent surgery to treat AAA were enrolled at 17 centers in the United
States. All patients were considered to be at low risk from aortic surgery. Patients who underwent endovascular repair
received a bifurcated Talent LPS stent graft; surgical control subjects underwent standard operative techniques. Inclusion
criteria were AAA larger than 4.0 cm in diameter, with proximal neck > 5 mm long and 14 to 32 mm in diameter, and
a 15 mm landing zone in at least one common iliac artery. Access requirements included one external iliac artery of 7 mm
caliber or larger. Preoperative anatomic evaluation included computed tomography and angiography. After stent-graft
placement, evaluation involved plain radiography and computed tomography performed before discharge and at 1, 6, and
12 months and yearly thereafter.
Results: There was no significant difference in early (<30 days) or late mortality between the two groups. Complications
were slightly higher in the surgical cohort. The stent graft group did better in terms of procedure duration, requirement
for general anesthesia and blood transfusion, and intensive care unit and hospital stay. There were three access or
deployment failures. Immediate surgical conversion was necessary in only 1 patient, and late conversion in 5 additional
patients. There were no aneurysm ruptures. Endoleak rate detected at CT (core laboratory validated) was 14% at 1 month,
12% at 6 months, and 10% at 12 months.
Conclusions: Compared with surgical control subjects, patients with AAA treated with the Talent LPS stent graft had
fewer complications and the same low operative mortality. Likewise, endovascular repair performed better than surgery
in the perioperative period, as measured with several key procedural indicators. Long-term follow-up of patients with the
stent graft will be essential to assess durability of these early results. (J Vasc Surg 2003;37:709-15.)
Endovascular devices have forever changed treatment
of abdominal aortic aneurysm (AAA). The concept of less
invasive endoluminal exclusion that can be achieved with-
out need for a major abdominal operation or cross-clamp-
ing of the aorta was exciting and, in truth, revolutionary.
The technology was developed at an explosive rate, culmi-
nating in Food and Drug Administration (FDA) approval
of two AAA stent-grafts in September 1999, a “short” 8
years after Parodi et al1 initially reported their “homemade”
endograft. Other devices are under investigation, and reg-
ulatory approval of additional stent grafts is likely in the
near future.
We report results of a pivotal clinical trial that compared
standard surgical repair with endovascular exclusion of
AAA with the Talent LPS stent graft system.
METHODS
Device. The Talent LPS stent graft (Medtronic
AVE, Santa Rosa, Calif) is a self-expanding, modular
device composed of serpentine nitinol stents inlaid in
monofilament woven polyester fabric (Figure). The
stents are spaced along a longitudinal nitinol connecting
bar that provides column strength. The delivery system is
a coaxial sheath with an internal pusher rod and a com-
pliant polyurethane balloon, located just ahead of the
top end of the device, that is inflated sequentially along
the length of the endograft to optimize apposition to the
vessel wall and between modular components. The Tal-
ent LPS system consists of a bifurcated main trunk that
contains the ipsilateral iliac limb and a short contralateral
stump, and the contralateral iliac limb. Configuration of
the proximal end incorporates a 15 mm long uncovered
stent (“bare spring”) designed for suprarenal fixation.
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Additional components are aortic and iliac extension
cuffs. The manufacturer offers a number of configura-
tional and dimensional customization possibilities for
both the basic system and the extensions.2 Range of
diameter for the aortic section is 16 to 36 mm, and for
the iliac limbs is 8 to 22 mm. Modular extensions involve
placement of overlapping segments, with the inner seg-
ment 2 mm larger in diameter, to achieve a blood-tight
seal at the overlap zone.
Clinical study design. The trial was a multicenter,
nonrandomized, prospective, controlled study designed to
compare standard open surgery with endovascular stent
graft repair for treatment of AAA in patients with low risk.
Regulatory approval for expansion to a pivotal trial was
granted by the FDA after safety of the Talent device was
demonstrated in a 1997 pilot study of patients with high
risk conducted at 6 centers in the United States.3 Several
high-risk and low-risk clinical studies have been conducted
wiht various Talent stent graft designs.4 This report focuses
on the pivotal Talent LPS low-risk controlled trial (IDE
#G970065) performed at 17 investigational sites. Patients
were enrolled between March 24, 1999 and September 19,
2000. Each study site received approval and oversight from
its respective institutional review board.
Trial centers. Participating institutions and investiga-
tors are listed at the end of this article.
Patient selection. Patients with low risk (Society for
Vascular Surgery/International Society for Cardiovascular
Surgery [SVS/ISCVS] score 0, 1, or 2)4,5 with nonrup-
tured AAA and aortoiliac aneurysm were included in the
trial. Aneurysms were 4.0 cm or larger in transverse diam-
eter or one and one-half times the diameter of the nonan-
eurysmal aorta, with infrarenal neck5 mm long and 14 to
32 mm in diameter, with less than 60-degree angulation.
Distance (length) between the lowermost renal artery and
the aortic bifurcation was 90 mm. Iliac artery criteria
included 15 mm minimum length landing zone, with di-
ameter of 8 to 18 mm in at least one common iliac artery,
and preservation of antegrade flow into at least one hypo-
gastric artery. Access requirements called for external iliac
arteries to be of 7 mm minimum caliber.
Exclusion criteria included the following: patient
deemed at high risk for elective surgical repair; circumfer-
ential mural thrombus at the proximal neck; “dominant”
inferior mesenteric artery in the setting of stenosed or
occluded superior mesenteric or celiac arteries; aneurysm in
the bilateral hypogastric artery; aneurysmal involvement of
both common iliac arteries with inability to preserve pa-
tency of at least one hypogastric artery; external iliac arteries
less than 7 mm; concomitant severe femoral artery or
infrainguinal arterial occlusive disease; known allergy to the
fabric or metal components of the device; bleeding diathe-
ses or coagulopathy; Marfan syndrome or other congenital
degenerative collagen disorder; systemic infection; history
of life-threatening allergic reaction to iodinated radioactive
contrast agents; acute myocardial infarction, stroke, or
major surgery within 3 months; and patient currently par-
ticipating in another clinical trial.
Preoperative assessment of AAA morphology. All
patients underwent conventional angiography with a cali-
brated catheter, and contrast medium–enhanced com-
puted tomography (CT) with 3 to 5 mm sections. The
following measurements were made in each patient by each
site’s investigators: proximal neck diameter immediately
below the lowermost renal artery (D1) and 10 mm distally
(D2); length of the neck (L1), aneurysm (L2), and distal
neck, if any (L3); distance from lowermost renal artery to
Bifurcated Talent LPS stent graft. Note uncovered nitinol stent
(“bare spring”) at proximal end.
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bifurcation (L4); angulation of the proximal neck; diameter
of the aneurysm (D3) and at the aortic bifurcation (D4);
distance (length) from aortic bifurcation to each hypogas-
tric artery origin; and diameter of common and external
iliac arteries.
Surgical control patients. The surgical cohort met
the same general inclusion and exclusion criteria as de-
scribed, with the exception of anatomic aspects. Patients
undergoing standard surgical repair because of unsuitable
morphologic features, mainly related to the neck and iliac
artery, constituted the largest subset in this cohort. Patients
meeting all requirements but ultimately refusing endovas-
cular repair were also eligible to become surgical control
subjects. Each investigational site was required to enroll a
minimum of 5 control patients.
Stent graft procedure. Endovascular implantation of
the Talent LPS stent graft was performed after administra-
tion of regional (spinal or epidural) or local anesthesia in
66% of patients or general anesthesia in 34% of patients.
Access to the common femoral arteries was by surgical
cutdown. A 22F or 24F (inner diameter) delivery sheath
was used to introduce the device into the aorta, followed by
deployment in the juxtarenal segment. Transrenal place-
ment of the uncovered stent (“bare spring”) was at inves-
tigator discretion. A bifurcated stent graft was used in every
instance; delivery and deployment of the contralateral limb
was with an 18F or 20F sheath. The implant procedure was
performed under fluoroscopic and angiographic guidance.
Composition of the interventional team varied across sites,
with only surgeons at some sites and combinations of
surgeons, radiologists, and cardiologists at other sites.
Surgical procedure in control patients. Concur-
rently, surgical control patients underwent repair with stan-
dard operative techniques, with general anesthesia in 94%
of patients and epidural anesthesia in 6% of patients. The
approach was either transabdominal or retroperitoneal, and
a tube or bifurcated prosthesis was used for aneurysm
replacement.
Follow-up evaluation. Patients receiving a stent graft
underwent predischarge two-view (anteroposterior and lat-
eral) plain abdominal radiography and CT to evaluate
device placement, graft patency, aneurysm size, renal artery
patency, and presence or absence of endoleak. CT protocol
included contrast and noncontrast phases, and 3 to 5 mm
sections. The same studies were repeated at 1, 6, and 12
months, and yearly thereafter. All films, both preoperative
and postoperative, were reviewed locally at each investiga-
tional site and at an independent core laboratory (Jobst
Vascular Center, Toledo, Ohio, under the direction of
Hugh G. Beebe, MD). Assessment focused on device-aorta
interaction, device migration or configurational changes,
proximal neck diameter, aneurysm sac diameter, and en-
doleaks.
Definitions and end points. The trial was designed to
assess the safety and clinical efficacy of endovascular exclu-
sion of AAA in patients with low surgical risk with the
Talent LPS stent graft, comparing its performance with the
outcome of standard surgical repair at 12 months and
beyond. Primary end points were technical success during
implantation and incidence of adverse events including
30-day mortality, aneurysm rupture, and surgical conver-
sion. Additional end points were related to procedural
events such as blood transfusion requirements and duration
of operation, and clinical utility parameters such as length
of stay in the hospital and intensive care unit (ICU) and
time to return to normal activities. Risk factor stratification
was assigned according to SVS/ISCVS guidelines,4,5 with
risk level scores of 0, 1, or 2 considered “low risk” and 3
considered “high risk.” Deployment success was defined as
ability to gain endovascular access and deliver the stent
graft to the intended site in the aorta. Technical success was
defined as successful deployment without endoleak at com-
pletion angiography. Serious adverse events included com-
plications resulting in need for additional procedures or
prolonged hospitalization.
Statistical analysis. Percentages with 95%confidence
intervals were calculated. 2 analysis and Fisher exact test
were used to compare rates between surgical and stent graft
groups. Mean values for age, aneurysm feature measure-
ments, and clinical utility parameters ICU and hospital stay
were calculated with the t test. Life table methods were
used to calculate log-rank P values for differences in survival
rate over time.
The study sponsor, Medtronic AVE, was involved in
design of the trial and data collection. However, the pri-
mary author and principal investigator (F.J.C.) had unlim-
ited freedom to contribute in all areas and unlimited access
to original data. He and the coauthors are solely responsible
for data analysis, manuscript preparation, and timing and
form of publication.
RESULTS
Two-hundred forty patients who received the stent
graft and 126 surgical control patients were enrolled. Case
spread among the investigational sites varied, with the most
active enrolling 41 patients (17%) and the least active
enrolling just 1 patient (0.4%). Most centers performed 5%
to 10% each of the endovascular repairs. Patient character-
istics for the stent graft and surgical cohorts are listed in
Table I. Patients in the stent graft group were slightly older
(mean age, 75.5 years) than the surgical control patients
(mean age, 70.0 years) and had more cardiac comorbid
conditions. There was no significant gender difference be-
tween the stent graft group (male, 90%; female, 10%) and
the surgical control group (male, 80%; female, 20%). An-
eurysm features (core laboratory validated) are summarized
in Table II. Of note, neck in 45.3% of patients was 26 mm
or larger in diameter, and neck length in 38.6% was 15 mm
or less, with proximal aneurysm neck 10 mm or shorter in
19% of all patients who received a Talent LPS stent graft.
Mean neck length in the total stent graft cohort was 25.3
mm (range, 16-36 mm), compared with 24.6 mm (range,
17-38 mm) in the surgical cohort. Mean follow-up was 318
days for the surgical group and 406 days for the stent graft
cohort.
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Procedural results. Deployment success was achieved
in 237 of 240 procedures (98.7%). Of the 3 failures, 2 were
access-related and thought to have occurred because of
inadequate external iliac arteries with associated calcifica-
tion. Immediate surgical conversion was performed in 1
patient, with successful outcome. In the other patient with
access failure, subsequent successful endovascular repair
with another stent graft device was performed several weeks
later. In the third patient with deployment failure the
sheath failed to retract to uncover the device. Careful
review of this event led to the conclusion that it was
probably related to equipment malfunction rather than
operator error. The aneurysm was not repaired, and the
patient was alive and well at the last follow-up (February 4,
2002), 16 months after the failed attempt at endovascular
repair. Placement of the device included crossing of one or
both renal arteries with the top end bare spring in 190
implants (80%). Modular extensions were used in 141 of
237 implants (60%). An aortic cuff only was used in 24
(10%), iliac extensions in 89 (38%), and both iliac and aortic
cuffs in 28 (12%). Eighty-nine patients (37.6%) received a
two-piece Talent LPS stent graft without any extensions.
Aneurysm exclusion without endoleak at completion an-
giography (technical success) was secured in 77% of cases.
Most intraoperative endoleaks were described as contrast
“blush” (type 4). A comparison of stent graft and surgical
cohorts in terms of anesthesia, blood loss, and other key
procedural indicators (Table III) shows that endovascular
repair produced better outcome in all categories.
Mortality and morbidity. All surgical patients sur-
vived the operation, for zero 30-day mortality. One patient
who received the stent graft died of complications from
lung cancer, for a mortality rate of 0.8%, not statistically
different from the surgical figure. Serious adverse events
occurring both early (30 days) and late (30 days) are
listed in Table IV; as expected, surgical control patients had
a significantly higher incidence of bleeding requiring trans-
fusion. Device-related and procedure-related complica-
tions occurred in 9 patients. Iliac limb occlusion, stenosis,
femoral artery injury, and deployment failure occurred in 1
patient each. The other complications were access-related
and included iliac artery dissection in 3 patients and vessel
perforation in 2 patients.
Endoleaks. Follow-up CT scans, as assessed indepen-
dently by the core laboratory, showed freedom from en-
doleak in 70% of patients at discharge, 86% at 1-month
follow-up, 88% at 6 months, and 90% at 12 months (Table
V). Among the latter, 7 were classified as type 1 and 8 as
type 2. Unfavorable neck anatomy did not influence en-
doleak rate. The incidence of endoleak at 12 months was
not statistically different for patients with short versus long
necks (4% and 13%, respectively; P  .2) or for those with
wide versus narrow necks (5% and 11%, respectively; P 
.4). Secondary endovascular repair for treatment of en-
doleak was undertaken in 3 patients after the initial stent
graft implantation: 1 patient underwent placement of an
aortic cuff to cover a type 1 endoleak 5 days postopera-
tively; 2 other patients with endoleak originating from the
distal attachment sites underwent placement of iliac exten-
sions at 1 and 11 months, respectively.
Aneurysm sac diameter changes and stent graft
migration. Stent graft migration was defined as 5 mm or
greater displacement of the, proximally or distally, as as-
sessed at CT. Similarly, the same 5 mm threshold was used
to denote significant increase or decrease in diameter of the
excluded aneurysm sac. According to findings corrobo-
rated by the core laboratory, only 3 instances of migration
and 2 incidences of sac growth were identified. In all other
patients the aneurysm was stable or shrinking aneurysm
after endovascular repair. Rates of diameter sac change and
migration were no different between patients with short
(15 mm) or wide (26 mm) necks (“bad necks”) and
those with long (15 mm) or narrow (26 mm) proximal
necks (“good necks”). Increase in diameter occurred in 1 of
Table I. Patient characteristics
Surgical control
group (%)
(n  240)
Stent graft
group (%) P
Comorbid conditions (n  126)
Angina 15 16 NS
Arrhythmia 11 24 .003
CABG 23 25 NS
Coronary artery disease 25 38 .02
Cancer 15 17 NS
Congestive heart failure 8 13 NS
COPD 18 21 NS
Stroke 13 14 NS
Diabetes 7 12 NS
Hypertension 75 70 NS
Myocardial infarction 30 38 NS
PTCA 3 9 .05
Peripheral vascular disease 19 19 NS
Renal dysfunction 8 14 NS
Smoking 82 74 NS
SVS/ISCVS risk stratification
SVS/ISCVS score
0 (none/low) 18 17
1 (mild) 61 48.5 .016
2 (moderate) 19 34
3 (high/severe) 2 0.5
CABG, Coronary artery bypass grafting; COPD, chronic obstructive pulmo-
nary disease; PTCA, percutaneous transluminal coronary angioplasty; NS,
not significant.
Table II. AAA architecture: stent graft group
Mean Range
SD(mm) (mm)
Neck length 25.3 5-80 3.8
Neck diameter 24.4 16-36 13.0
Sac diameter 56.7 40-100 9.6
Right CIA diameter 14.7 7.8-60 5.1
Left CIA diameter 14.1 7.6-45 4.2
AAA, Abdominal aortic aneurysm; CIA, common iliac artery; SD, standard
deviation.
JOURNAL OF VASCULAR SURGERY
April 2003712 Criado et al
29 patients (3%) with a wide neck versus 1 of 99 patients
(1%) with a narrow neck (P  .4), and in none of 44
patients (0%) with a short neck versus 2 of 85 patients (2%)
with a long neck (P  .5). Stent graft migration was noted
in 1 of 53 patients (2%) with a short neck versus 2 of 105
patients (2%) with a long neck (P  1.0), and in 1 of 40
patients (3%) with a wide neck and 2 of 117 patients (2%)
with a narrow neck (P  1.0).
Surgical conversion. Six patients underwent surgical
conversion after implantation of a Talent LPS stent graft.
The first was an intraoperative conversion during the initial
implant procedure when access could not be achieved. The
other 5 procedures were performed much later. In 1 pa-
tient, conversion was performed at 23 months, because of
flow-limiting compression or kinking causing recurrent
endograft thrombosis. In 1 patient surgery was performed
at 21 months when placement of a proximal cuff, with a
modular component from a different device, resulted in
coverage of the renal arteries. Surgery was performed at 13
months in 1 patient in whom purulent infection of pre-
sumed hematogenous origin developed in the excluded
AAA sac, necessitating endograft excision and conversion
to standard open repair. Surgical treatment was also under-
taken in another patient with an enlarging pararenal aortic
pseudoaneurysm believed to be the result of catheter-
related dissection during the initial endograft implant. In
the sixth patient surgical conversion was performed because
of an enlarging AAA sac, but without demonstrable en-
doleak.
Aneurysm rupture. No aneurysms ruptured, either
after stent graft implantation or surgical repair.
Late mortality (>30 days). Six patients (4.8%) in the
surgical group died, compared with 20 in the stent graft
cohort (8.3%). The difference was not statistically signifi-
cant (P  0.4). None of the deaths appeared to be aneu-
rysm-related, as assessed by the investigators and affirmed
by the Data Safety and Monitoring Board. Correlation
between SVS/ISCVS risk score and mortality could not be
established.
Wire fracture. Plain abdominal x-ray films demon-
strated nitinol wire fractures in 11 stent grafts. The frac-
tures involved one of the stent springs in the main body of
the device in 3 cases and the longitudinal connecting bar of
the iliac limb in the other 8. Thus far no clinical events
Table III. Key procedural outcome indicators
Indicators
Surgical control
group Stent graft group P
Procedure duration (min) 221.2  101.6 172.2  77.1 .0001
Range 85-581 19-540
Estimated blood lose (mL) 1541.6  1218.5 345.5  337.2 .0001
Transfusion required (%) 67 11 .0001
Length of stay
Intensive care unit (hr) .0001
Mean 55.2 14.3
Range 0-408 0-832
Hospital (d) .0001
Mean 8.7 4.6
Range 3-47 1-69
Table IV. Serious adverse events (complications)
Stent graft
group (%)
Surgical control
group (%) P
Within first 30 days
Bleeding
requiring
transfusion
28 73 .0001
Vascular 3 5 .2
Pulmonary 1 4 .07
Cardiac 3 4 .5
Septic 1 2 .2
Wound 3 5 .1
Renal 3 4 .5
Neurologic 3 0 .07
Gastrointestinal 1 2 .6
After 30 days
Vascular 3 1 0.3
Pulmonary 2 2 0.3
Cardiac 7 3 0.1
Septic 1 1 0.4
Wound 1 1 0.4
Renal 1 1 0.4
Neurologic 3 1 0.3
Gastrointestinal 1 3 0.2
Table V. Endoleaks: stent graft cohort
Follow-up Endoleak at CT (CoreLab)
1 mo (n  190) Type 1 11
Type 2 16
Indeterminate 0
Total 27 (14%)
6 mo (n  179) Type 1 8
Type 2 13
Indeterminate 0
Total 21 (12%)
12 mo (n  159) Type 1 7
Type 2 8
Indeterminate 1
Total 16 (10%)
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directly attributable to a metal component break have
occurred. In 1 patient with a stent spring fracture, an
enlarging aneurysm neck and downward migration of the
device prompted secondary repair with placement of an
aortic cuff. The patient is doing well, the aneurysm sac is
shrinking, and there is no detectable endoleak.
DISCUSSION
Several published reports have confirmed that, com-
pared with standard open surgery, endovascular stent graft
repair of AAA in carefully selected patients can be achieved
with lower morbidity and the same low operative mortali-
ty.6,7 In addition, immediate postoperative recovery tends
to be shorter and uneventful. Results achieved in this
pivotal trial met such expectations. Patient outcome after
stent graft intervention was particularly impressive when
considering the challenging nature of the endovascular
cohort, which included a large number of patients with
difficult anatomy and comorbid conditions. Unlike previ-
ous stent graft studies,6,7 the Talent trials adopted a rather
flexible patient enrollment policy that gave investigators
great freedom to choose patients, with little if any oversight
or control from the sponsor (manufacturer). Such policy,
together with the unique features of the Talent technology,
including customization, large sizes, and suprarenal fixa-
tion, help explain enrollment of a relatively high proportion
of patients with unfavorable proximal neck anatomy.
Twelve-month outcome was not statistically different for
patients with “good” versus “bad” necks in terms of en-
doleak, migration, or aneurysm diameter change. The over-
all endoleak rate of 10% at 12 months, detected at CT and
validated with core laboratory scrutiny, is one of the lowest
so far reported in a stent graft trial. We can only speculate
on the possible reasons for this, such as suprarenal fixation
and oversizing. The number of type 1 endoleaks, however,
was somewhat higher than expected, and this may reflect
difficulties related to unfavorable proximal neck anatomy.
Rates of device migration (2%) and aneurysm sac enlarge-
ment (2%) were also found to be quite low. It is important
to emphasize, however, that these figures represent early
and midterm results only, and that long-term monitoring
of patients will be essential to substantiate durability of
repair and the device.
From a technical standpoint, the Talent device is simple
to deliver and deploy. The relatively large sheath (22F or
24F) can limit applicability in patients with small-caliber
access arteries. The rather small number of enrolled female
patients (10%) reflects such limitation, although the same
has been reported in other stent graft experiences.6,7 The
relatively high use of extension cuffs (60% overall) merits
further discussion. Careful review of a large majority of
these cases by the study’s principal investigator (F.J.C.)
failed to clarify the issue. While poor planning and technical
difficulties at stent graft delivery and deployment could be
implicated in theory, we failed to uncover evidence of this.
It can be argued that limiting endograft component usage
is desirable; however, such practice did not seem to com-
promise achievement of acceptable technical results, with
endoleak-free aneurysm exclusion in a large percentage of
cases. The finding of several instances of fatigue-related
breaks of the nitinol wire is cause for concern. Stent spring
and connecting bar fractures have proved largely inconse-
quential so far; however, potential for clinical adverse
events related to such device failures cannot be denied.
Close long-term surveillance is warranted. A modified de-
vice (Enhanced Talent LPS) has been developed that incor-
porates the engineering “solutions” that prevent wire metal
fractures at bench testing. A new (confirmatory) clinical
trial is under way to assess the performance of the enhanced
device in the clinical setting.
Institutions and investigators participating in this trial
included the following: Union Memorial Hospital/Med-
Star Health, Baltimore, Md, Frank J. Criado, MD; Miami
Cardiac and Vascular Institute, Miami, Fla, Gary J. Becker,
MD, and Barry T. Katzen, MD; Montefiore Medical Cen-
ter, Bronx, NY, Frank J. Veith, MD; Medical University of
South Carolina, Charleston, SC, Renan Uflacker, MD;
Arizona Heart Institute, Phoenix, Ariz, Edward B. Di-
ethrich, MD; Brigham Women’s Hospital, Boston, Mass,
Michael Belkin, MD; Hartford Memorial Hospital, Hart-
ford, Conn, Michael Hallisey, MD; St John’s and William
Beaumont Hospitals, Detroit, Mich, Michael Khoury, MD,
and Paul Bove, MD; Morton Plantation Hospital, Largo,
Fla, Alexander Balko, MD; Hospital of the University of
Pennsylvania, Philadelphia, Pa, Ronald M. Fairman, MD,
Jeffrey Carpenter, MD, and Michael Golden, MD; Strong
Memorial Hospital, Rochester, NY, Richard Green, MD;
The Sanger Clinic, Charlotte, NC, Robert Allen, MD;
Harbor UCLA Medical Center, Torrance, Calif, Rodney A.
White, MD; Stanford University Medical Center, Palo
Alto, Calif, Thomas J. Fogarty, MD; Yale University Med-
ical Center, New Haven, Conn, Patricia Cole, MD; The
Cleveland Clinic, Cleveland, Ohio, Roy K. Greenberg,
MD; St Luke’s Medical Center, Phoenix, Ariz, Richard
Heuser, MD.
We are indebted to all clinical investigators and research
coordinators for their contribution to this trial. We also
wish to thank the Medtronic Talent support group, espe-
cially Simon Fuger, Jeff Elkins, Deepak Srikant, Carol
Barbre, and Andre Butler.
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